KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Operating Expenses (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Other Operating Expenses for 9 consecutive years, with -$3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 62.5% year-over-year to -$3.0 million, compared with a TTM value of -$18.0 million through Dec 2025, down 228.57%, and an annual FY2025 reading of -$18.0 million, down 228.57% over the prior year.
  • Other Operating Expenses was -$3.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from -$6.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $52.0 million in Q1 2022 and bottomed at -$8.0 million in Q4 2024.
  • Average Other Operating Expenses over 5 years is $12.5 million, with a median of $5.5 million recorded in 2021.
  • The sharpest move saw Other Operating Expenses soared 940.0% in 2022, then crashed 400.0% in 2025.
  • Year by year, Other Operating Expenses stood at $25.0 million in 2021, then fell by 24.0% to $19.0 million in 2022, then plummeted by 68.42% to $6.0 million in 2023, then tumbled by 233.33% to -$8.0 million in 2024, then soared by 62.5% to -$3.0 million in 2025.
  • Business Quant data shows Other Operating Expenses for TEVA at -$3.0 million in Q4 2025, -$6.0 million in Q3 2025, and -$4.0 million in Q2 2025.